Major Noncerebral Bleeds

	In ASSENT-2, there were 20% fewer major noncerebral bleeding events* in patients treated with TNKase vs. Activase® (Alteplase)1
	Statistically significant fewer blood transfusions were required in patients treated with TNKase vs. Activase (4.25% vs. 5.49%, p=0.0002)1
	The most frequent adverse reaction associated with TNKase is bleeding. Should serious bleeding occur, concomitant heparin and antiplatelet therapy should be discontinued immediately.
*	Major bleeding is defined as bleeding requiring blood transfusion or leading to hemodynamic compromise.

Indication:
For use in mortality reduction associated with acute myocardial infarction (AMI). Treatment should be initiated as soon as possible after the onset of AMI symptoms.

Important Safety Information:
TNKase therapy in patients with acute myocardial infarction is contraindicated in the following certain situations (eg, active internal bleeding, history of cerebrovascular accident, known bleeding diathesis, severe uncontrolled hypertension) because of an increased risk of bleeding [See CONTRAINDICATIONS in full prescribing information].

The most common complication encountered during TNKase therapy is bleeding. Should serious bleeding (not controlled by local pressure) occur, any concomitant heparin or antiplatelet agents should be discontinued immediately.

In certain conditions (eg, recent major surgery, cerebrovascular disease, hypertension) the risk of TNKase therapy may be increased and should be weighed against the anticipated benefits. [See WARNINGS in full prescribing information].

Cholesterol embolism has been reported rarely in patients treated with all types of thrombolytic agents; the true incidence is unknown.

Coronary thrombolysis may result in arrhythmias associated with reperfusion. It is recommended that anti-arrhythmic therapy for bradycardia and/or ventricular irritability be available when TNKase is administered.

Please see full prescribing information for additional important safety information.